Evidence map›Paper›PMID 40873355›Full record

ReviewCurrent drug research reviews2026

Advances in Piperazine-based Compounds for Antimicrobial Drug Development: Design, SAR, and Therapeutic Potential.

Shagun Aggarwal, Divya Jain, Parminder Kaur, Kuldeep Singh

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current drug research reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Shagun AggarwalUniversity Institute of Pharma Sciences (UIPS), Chandigarh University, Gharuan, Mohali, 140413, Punjab, India.
Divya JainDepartment of Microbiology, School of Applied & Life Sciences, Uttaranchal University, Dehradun, 248007, Uttarakhand, India.
Parminder KaurUniversity Institute of Pharma Sciences (UIPS), Chandigarh University, Gharuan, Mohali, 140413, Punjab, India.
Kuldeep SinghDepartment of Pharmacology, Institute of Pharmaceutical Research, GLA University, Mathura, Uttar Pradesh, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The rise of antimicrobial resistance has intensified the need for novel therapeutic agents to combat infectious diseases. Among various heterocyclic scaffolds, piperazine has emerged as a promising nucleus in drug discovery due to its structural versatility and ability to enhance bioactivity. This review explores the role of piperazine-based compounds in antimicrobial drug development, focusing on design strategies, Structure-Activity Relationships (SAR), and therapeutic applications. Structural modifications of piperazine derivatives, including the incorporation of electron-withdrawing groups (Cl, Br, NO

Indexed as

Anti-Bacterial AgentsAnti-Infective AgentsDrug DevelopmentPiperazinesAnimalsDrug DesignDrug DiscoveryHumansPiperazineStructure-Activity RelationshipAnti-Bacterial AgentsAnti-Infective AgentsPiperazinePiperazinesantimicrobial resistancedrug discoverymolecular dockingPiperazine derivativesstructure-activity relationshiptherapeutic potential

Identifiers

PMID40873355

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.